Search results: (10000)
News FEIBA in Real Clinical Practice – Fresh Data from the Observational Study FEIBA GO
FEIBA GO (Global Outcome) was a prospective observational study evaluating the long-term administration of FEIBA, its safety, efficacy, and quality of life for patients with hemophilia A or B and high-titer inhibitors (high responders), who were receiving aPCC in routine clinical practice. The study, whose results were recently published, was conducted at 25 centers in 11 countries.
News Doc. Debora Karetová: Do Not Underestimate the Complexity of CHVO Treatment and Early Stages of the Disease
Are you applying the optimal approach to the treatment of chronic venous disease? What do the new Czech recommendations bring? And what is the current role of venopharmacs in treatment management? You can read all about this in an interview with the chair of the Czech Angiological Society ČLS JEP Doc. MUDr. Debora Karetová, CSc., from the 2nd Internal Clinic – Clinic of Cardiology and Angiology at the 1st Faculty of Medicine, Charles University, and General University Hospital in Prague.
News Venetoclax Treatment Strategies in Patients with CLL
One of the new targeted preparations in the treatment of chronic lymphocytic leukemia (CLL) is the Bcl-2 inhibitor venetoclax. Its significant advantage is the potential to achieve deep remission, including undetectable minimal residual disease (MRD). Unlike other targeted drugs, it can be administered for a limited period of time. The following text presents current data from clinical trials and information on the strategy of selecting and sequencing targeted CLL treatment.
News Cardiovascular System Affection in Children with Noonan Syndrome
Noonan syndrome is a genetically conditioned disease classified among the so-called RASopathies, caused by a germline mutation in the genes of the RAS/MAPK signaling pathway. Among other things, children with this disease typically present with cardiovascular system involvement.
News Adherence to Treatment of Multiple Sclerosis: How to Enhance It and What Interesting Insights Emerged from Current Research?
Therapeutic options for patients with multiple sclerosis (MS) utilizing disease-modifying drugs (DMDs) have continued to expand in recent years. However, achieving their full benefit is critically dependent on adherence to treatment. Nonadherence is demonstrably linked to an increased risk of relapses, faster progression of disability, higher treatment costs, and higher mortality. We present a summary of factors affecting adherence to treatment in MS patients, including the influence of the chosen therapy from a 2022 review and subsequent studies.
News Candesartan is beneficial in heart failure with mildly reduced ejection fraction
Analysis of data from the CHARM study showed that in patients with heart failure with mildly reduced ejection fraction (HFmrEF 0.40–0.49), candesartan compared to placebo reduces the risk of death from cardiovascular (CV) causes or hospitalization for heart failure similarly to patients with reduced ejection fraction (HFrEF < 0.40).
News Dual therapy improves not only lung function but also quality of life in COPD patients
Chronic obstructive pulmonary disease (COPD) reduces the quality of life of patients and is one of the main causes of morbidity and mortality. According to international recommendations, the initial pharmacotherapy is recommended as monotherapy with LAMA (long-acting muscarinic antagonists) or LABA (long-acting beta-agonists), or their combination. A pooled analysis of 4 studies compared the early addition of LABA to LAMA in patients with moderate to severe COPD.
News Variability of COPD Symptoms During the Day and Impact on Patients' Morning Routine – Survey Results
Chronic obstructive pulmonary disease (COPD) is viewed, unlike bronchial asthma, as a condition with a more chronic course and less variability of symptoms throughout the day. The study presented below aimed to clarify whether these patients experience deterioration at certain times of the day and how this affects their daily lives.
News One Step Closer to Understanding the Placebo Effect in Pain Treatment
Neuroscientists from the USA appear to have advanced our understanding of the placebo effect in pain relief. Their findings, recently published in Nature, open the possibility of influencing the described pain control pathway using drugs or neurostimulation.
News Bimekizumab – Higher Chance of Complete Skin Healing in Moderate to Severe Psoriasis?
In August 2021, the European Medicines Agency (EMA) approved bimekizumab (Bimzelx LP) as the first psoriasis treatment that selectively and directly inhibits interleukins IL-17A and IL-17F. It is intended for the treatment of moderate to severe plaque psoriasis in adults for whom systemic treatment is appropriate. The approval is based on three Phase III clinical studies in which bimekizumab demonstrated a very high rate of skin healing compared to placebo and active treatments like ustekinumab and adalimumab, as well as good tolerability.
News Chairwoman of Revma Liga ČR: I Hope We Improve Our Approach and Treatment of Osteoporosis in the Czech Republic
Patients with inflammatory rheumatic diseases have a significantly increased risk of developing osteoporosis and related fractures. At the same time, this disease is considerably underestimated in the Czech Republic, and more attention is given to it only at the stage of osteoporotic fractures. To what extent does the patient organization Revma Liga ČR, which unites patients with rheumatic diseases, engage in this issue? We asked its chairwoman Edita Müllerová.
News New Hematological Biomarker for Early Diagnosis of Sepsis
Sepsis is one of the leading causes of mortality and healthcare expenditure worldwide. Early diagnosis and treatment of septic conditions improve patient prognosis. However, the initial symptoms of sepsis can be difficult to distinguish from other acute conditions due to similar symptomatology. The results of the study presented below indicate that a new hematological biomarker has the potential to facilitate the early diagnosis of sepsis.
News EHL preparations have the potential to change the quality of life for people with hemophilia
Within the therapeutic modalities for hemophilia, the current era offers a number of preparations. Newer extended half-life (EHL) replacement therapies can provide hemophiliacs with better protection against bleeding and allow for greater physical activity.
News How do IL-17 and IL-23 inhibitors fare in the treatment of psoriasis in direct comparison?
A recent study published in the British Journal of Dermatology is only the second paper to provide a direct comparison of the efficacy and onset speed of treatment with IL-17 and IL-23 inhibitors in patients with moderate to severe plaque psoriasis. The authors monitored the early response to treatment (at week 12), and the efficacy and safety of ixekizumab and guselkumab.
News Quo vadis, erdostein? Or the current and future potential of erdosteine in practice
Erdosteine has a well-established place in the therapy of acute respiratory diseases in children. Its mucolytic and antibacterial properties are very well documented. Recently, research has focused primarily on the anti-inflammatory and antioxidant effects of this molecule. Attention is also being paid to its antiviral potential. How does it stand in this regard?
News Adequate Anti-Xa Levels Are More Often Achieved in Trauma Patients When Dosing Enoxaparin Based on Weight
Thromboembolic disease (TED) is a well-known preventable cause of morbidity and mortality in trauma patients. To improve their prognosis, pharmacological thromboprophylaxis, such as with low molecular weight heparins (LMWH), is an essential part of treatment. However, previously published studies have pointed out that standard dosing of LMWH may be associated with insufficient levels of activity measured using the anti-Xa parameter.
News Recommendations for Substitution Therapy with Immunoglobulins in Hemato-oncological Patients with Secondary Immunodeficiency – Expert Consensus According to the DELPHI Methodology
Substitution therapy with immunoglobulins is used not only for patients with primary immunodeficiencies. Below, we briefly summarize recommendations concerning hemato-oncological patients with secondary immunodeficiency.
News Debate on Sepsis Biomarkers 'on Blood'
Sepsis represents a major cause of death from infectious diseases. Early identification of patients with a prognosis of sepsis is therefore crucial for their survival and prognosis. In addition to traditional biomarkers such as C-reactive protein (CRP) or procalcitonin (PCT), other markers are being sought that could be used in the differential diagnosis of sepsis. This issue was also addressed at a symposium organized by Beckmann Coulter, which took place on April 28, 2022, as part of the Colours of Sepsis congress in Ostrava.
News The Future of Multiple Sclerosis – Time for a Change in Classification?
What are the latest findings on the etiopathogenesis of multiple sclerosis? Are they reflected in the current classification? And what will future therapy look like?
News Lorlatinib in a Patient with Meningeal Carcinomatosis – Case Report
The prognosis of patients with meningeal carcinomatosis is unfavorable. The following case report demonstrates how a targeted mechanism of action and optimal drug penetration into the central nervous system (CNS) can not only quickly relieve patients from neurological problems associated with meningeal infiltration, but also prolong their survival.
News Dust Mite Allergies: Common Does Not Mean Trivial
Dust mite allergies are almost ubiquitous problems that we perceive as part of the 'broader norm.' However, patients do not see it this way, so we should not lose sight of it.
News Combination of Targeted Therapy with Chemo in 1st Line in Patients with Left-Sided wtRAS mCRC
The preferred targeted therapy added to the combination with standard chemotherapy (CHT) for left-sided metastatic colorectal cancer (mCRC) with non-mutated RAS oncogene should be an antibody against the epidermal growth factor receptor (anti-EGFR), not against the vascular endothelial growth factor (anti-VEGF). This is based on a direct comparison of anti-EGFR panitumumab and anti-VEGF bevacizumab in the Japanese phase III PARADIGM study. The results were presented at the ASCO 2022 annual meeting.
News Romiplostim Before Splenectomy in a Patient with ITP - Case Report
In the following case report from authors at a university hospital in Barcelona, the successful use of romiplostim as a second-line treatment before planned splenectomy in a patient with immune thrombocytopenia (ITP), liver cirrhosis, and iatrogenic Cushing's syndrome is demonstrated.
News Omalizumab and Treatment of Severe Refractory Asthma in Pregnant Women
Omalizumab is commonly recommended for the treatment of severe refractory asthma. A special group of patients are pregnant women with asthma, for whom the risks of inadequately treated asthma must be weighed against the risks of biological treatment for the fetus. EXPECT is a pregnancy registry that has served since 2006 as a prospective observational study; its aim is to collect data on women treated with omalizumab during pregnancy and compare it with data from asthmatic women who did not receive omalizumab.